Intensive coronary care: current status and future prospects.
D000700:Analgesics / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000628:therapy; D001282:Atrial Flutter / Q000628:therapy; D001285:Atropine / Q000627:therapeutic use; D001919:Bradycardia / Q000628:therapy; D003325:Coronary Care Units; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D004554:Electric Countershock; D005544:Forecasting; D006333:Heart Failure / Q000628:therapy; D006760:Hospitalization; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008012:Lidocaine / Q000627:therapeutic use; D008952:Mobile Health Units; D008991:Monitoring, Physiologic; D012770:Shock, Cardiogenic / Q000628:therapy; D013610:Tachycardia / Q000628:therapy; D013614:Tachycardia, Paroxysmal / Q000628:therapy; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000700:Analgesics; D000889:Anti-Arrhythmia Agents; D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents; D001285:Atropine; D008012:Lidocaine